Kopran Ltd

NSE
KOPRAN •
BUY

1W Return

-%

1M Return

-%

6M Return

-%

1Y Return

-%

3Y Return

-%

Start SIP in Kopran Ltd
Stock Performance
52 Week Low - High
Today’s Low - High

Open

Prev. Close

Total Traded Value

View details of Market Depth
Fundamental

Market Cap (in crs)

Face Value

Turnover (in lacs)

Key Metrics
Qtr Change %
174.79% Gain from 52W Low
-0.2
TTM PE Ratio
Above industry Median
31.5
Price to Book Ratio
Below industry Median
2.9
Dividend yield 1yr %
High in industry
1.1
TTM PEG Ratio
PEG TTM is much higher than 1
3.2
RSI
RSI is mid-range
49.8
MFI
MFI is mid-range
65.6

Kopran Ltd Key Financials

*All values are in ₹ Cr.

Kopran Ltd shareholding Pattern

Promoter
44.5%
Foreign Institutions
0.5%
Domestic Institutions
0.1%
Public
54.9%

Kopran Ltd Technical Analysis

Moving Averages Analysis
Moving Averages Analysis
Current Price
Bullish Moving Averages
8
Bearish Moving Averages
8
5Day EMA
264.20
10Day EMA
264.80
12Day EMA
264.90
20Day EMA
264.70
26Day EMA
264.20
50Day EMA
260.40
100Day EMA
248.10
200Day EMA
226.40
Delivery & Volume
Resistance & Support
262.75
Pivot
Resistance
First Resistance
266.10
Second Resistance
268.40
Third Resistance
271.75
Support
First Support
260.45
Second support
257.10
Third Support
254.80
Relative Strength Index
49.78
Money Flow Index
65.64
MACD
0.66
MACD Signal
1.29
Average True Range
12.92
Average Directional Index
17.15
Rate of Change (21)
2.25
Rate of Change (125)
16.44

Kopran Ltd Company background

Founded in: 1958
Kopran Ltd., incorporated on April 26, 1958, was promoted by the Somani group and is controlled by Parijat Enterprises. The company came out with a public issue at a premium, in Nov.92, to finance its backward integration project to produce drug intermediates for semisynthetic drugs, and also to expand its antibiotic facility.Kopran manufactures pharmaceutical finished dosage forms and bulk drugs and distributes electronic equipment. It manufactures semisynthetic penicillin and is among the worlds highest producers in amoxycillin. Kopran also makes penicillinG acylase, an enzyme made through fermentation. It has technical collaborations with Gesellschaft Fur Biotechnologische, Germany Yuhan Corporation, South Korea Ciba Corning Diagnostic, US and Adac Laboratories, US.Koprans bulk drug plant has been approved by the US FDA and the UK regulatory authorities. In 1995, the company was awarded the Quality Excellence award by the Indian Drug Manufacturers Association. Koprans high growth rate in exports has been recognised by a number of awards from CHEMEXCIL and the Ministry of Commerce.The company launched new products like AZ1 Caps, Klodip Tabs, Moclox Kid Tabs, Amyn Kid Tabs, TiniNF, Amyn Caps and Amyn Dry Syrup. Kopran entered into a joint venture with M/s Industrial Promotion Services Ltd to take over a running unit viz Kampala Pharmaceuticals Industries Ltd in Uganda.The company has been ranked as amongst the top few fastest growing companies in India(ORG MargJune 2000). It closed down its manufacturing facility at Saki Naka, Andheri, Bombay. Globalpharma, a joint venture with Dubai Investments Corporation started commercial production in the first quarter of 2002.The company has increased its installed capacity of Liquids by 3.00 lakhs of Litres during 2001 and consequent of this capacity expansion the total installed capacity has gone up to 12.00 lakhs of Litres.The company has also increased its installed capacity of Tablets Capsules by 270 crores(Nos) and the total capacity has gone up to 1080 crores(Nos).In Feb. 2001, Kopran tied up with EMerck for comarketing a new antiinflammatory drug, Rofecoxib, in India. Rofecoxib is one of the fastmoving nonsteroid antiinflammatory drugs (NSAID),has been launched in the international market. The Company also launched Cholestat (Atorvastatin a cholesterol reducer) and further gave comarketing rights for Atorvastatin to EMerck (India). The company had launched new products in therapeutic groups like Asthma,Cardiology,Diabetes and Lifestyle products during 2003.The company has obtained approval from European Directorate for Quality of Medicines(EDQM) in September 2003. Upgradation of Formulation Manufacturing facility took place to meet with the latest International Regulatory Norms.The United Kingdom Medicines and Healthcare Products Regulatory Agency(UK MHRA) is expected to inspect the facilities in the first quarter of 2004.Kopran Pharmaceuticals Ltd., the Company marketing the SMYLE brand of products was merged into the Company effective from 1st March, 2005. The Company introduced two new bulk drugs viz. Pregabalin and Cefditorin during the year 2007. The Company during the FY 201415 sold the Active Pharmaceuticals Ingredients (API) business on slump sale basis to its subsidiary Kopran Research Laboratories Ltd. at a consideration of Rs 110 Crores on 30th March, 2015. Similarly, the Consumer Care Division was sold w.e.f 1 April 2015.
Read More

Kopran Ltd FAQs

Kopran Ltd shares are currently priced at 263.8 on NSE and 263.55 on BSE as of 2/22/2024 12:00:00 AM. Please be aware that stock prices are subject to continuous fluctuations due to various factors.

The past 1-year return of Kopran Ltd [KOPRAN] share was 119.19. The Kopran Ltd [KOPRAN] share hit a 1-year low of Rs. 96 and a 1-year high of Rs. 292.3.

The market cap of Kopran Ltd is Rs. 1271.8 Cr. as of 2/22/2024 12:00:00 AM.

The PE ratios of Kopran Ltd is 51.17 as of 2/22/2024 12:00:00 AM.

The PB ratios of Kopran Ltd is 3.24 as of 2/22/2024 12:00:00 AM

You can easily buy Kopran Ltd shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

Open Demat Account
or Resume your Application
+91 -

personImage